BTNL2 and neoplasm: To further examine the role of IL-17A in tumour regression following BTNL2 blockade, we neutralized IL-17A in tumour-bearing mice and found that this completely abolished the anti-tumour effect of BTNL2 blockade (Fig. 2f).